Why Does MEN2 Require Preventative Thyroid Surgery?
At a Glance
Children with MEN2 or a RET gene mutation face a near 100% risk of developing aggressive medullary thyroid cancer. To ensure a long-term cure, doctors perform a preventative surgery called a prophylactic thyroidectomy to remove the thyroid before cancer can form.
It is completely normal to feel confused and protective when a doctor suggests removing your child’s thyroid—especially when they do not currently have cancer. In children with a known Multiple Endocrine Neoplasia type 2 (MEN2) condition caused by a RET gene mutation, the risk of developing a highly aggressive type of thyroid cancer is nearly 100% [1]. Because this specific cancer, called Medullary Thyroid Cancer (MTC), spreads very quickly once it starts, the safest and most effective cure is to remove the thyroid gland before the cancer ever has a chance to form [2][3]. This preventative approach is called a prophylactic thyroidectomy.
The Connection Between RET Mutations and Thyroid Cancer
The RET gene provides instructions that help cells in the body communicate. When there is a mutation (a typo in the gene’s instructions), it causes certain cells in the thyroid gland to grow out of control [1][4].
The thyroid contains “C-cells.” In children with a RET mutation, these C-cells first begin to multiply harmlessly, a pre-cancerous stage known as C-cell hyperplasia [5][6]. However, because of the genetic mutation, it is almost inevitable that these pre-cancerous cells will eventually turn into Medullary Thyroid Cancer [7]. Because MTC is very aggressive and harder to treat once it spreads, doctors intervene during the pre-cancerous stage to ensure a long-term cure [8][5]. Because this mutation is inherited, a genetic counselor can also help determine if siblings or other family members need testing [9].
Why Timing is Everything
The decision of when to perform the surgery is carefully based on your child’s specific genetic mutation and blood tests. The American Thyroid Association (ATA) groups RET mutations into three risk levels to guide exactly when a child should have surgery [10][11]:
- Highest Risk (Usually MEN2B): For these specific mutations, abnormal cell growth can begin within the first months of life. Surgery is typically recommended during the child’s first year of life [10][11].
- High Risk (Usually MEN2A): For high-risk MEN2A mutations (like codon 634), the cancer grows slightly slower, but surgery is still usually recommended before the child reaches age 5 [10][12].
- Moderate Risk (Other MEN2A): In this group, the timeline varies from person to person. The decision of when to operate is highly individualized and depends heavily on continuous blood monitoring [10][13].
Monitoring with Calcitonin
For children in the moderate risk group, or those awaiting surgery, your doctor will closely monitor your child’s blood for a hormone called calcitonin. C-cells naturally produce calcitonin, so as the number of C-cells increases, calcitonin levels in the blood will rise [14][15].
By regularly testing your child’s basal (resting) calcitonin levels—which may require blood draws every 6 to 12 months—doctors can spot the very earliest signs that the C-cells are multiplying. This acts as a biological early-warning system to pinpoint the safest, most effective time for surgery [16][17].
Surgery Safety and Life Afterward
Preventative thyroid removal in children is generally very safe and highly successful at preventing cancer [2][18]. A typical hospital stay for recovery lasts just 1 to 3 days [19].
However, the thyroid sits very close to the parathyroid glands (which control calcium) and the vocal cord nerves. Temporary drops in calcium levels (hypocalcemia) can happen, and there is a rare risk of temporary or permanent voice changes or hoarseness [19][20]. Permanent complications occur in fewer than 3% of cases [19][18]. Because of the delicate location of the thyroid in a child’s small neck, it is vital that the surgery is performed at a specialized center by a high-volume pediatric endocrine surgeon [21][22].
After the thyroid is removed, your child will take a daily thyroid hormone replacement pill for the rest of their life to support their normal growth, metabolism, and development [18]. For infants and toddlers, this medication is easily managed by crushing the pill and mixing it with a few drops of water, formula, or breastmilk [18]. As your child grows, they will need regular blood tests to ensure their hormone dose is correctly adjusted for their increasing size [18].
Common questions in this guide
Why does my child need their thyroid removed if they don't have cancer yet?
At what age will my child need preventative thyroid surgery for MEN2?
What is calcitonin and why does my child need blood tests for it?
What happens after my child's thyroid is removed?
Is a prophylactic thyroidectomy safe for babies and young children?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific RET mutation (codon number) does my child have, and what ATA risk category does it fall into?
- 2.How many pediatric prophylactic thyroidectomies do you perform each year?
- 3.What is your personal complication rate for permanent hypocalcemia or nerve injury in children?
- 4.How frequently will my child need blood draws to check their calcitonin and CEA levels before surgery?
- 5.Who will manage my child's thyroid hormone replacement medication as they grow?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (22)
- 1
Molecular diagnostic approaches in detecting rearranged during transfection oncogene mutations in multiple endocrine neoplasia type 2.
Gopinath S, Ramaiyan V
World journal of clinical cases 2024; (12(31)):6436-6440 doi:10.12998/wjcc.v12.i31.6436.
PMID: 39507119 - 2
The Long-Term Cure of Patients With Hereditary Medullary Thyroid Carcinoma: 40 Years of Follow-Up in a Single Center.
Raue F, Bruckner T, Frank-Raue K
Deutsches Arzteblatt international 2024; (121(20)):657-664.
PMID: 39285761 - 3
Current surgical management in RET mutation carriers [Aktualne postępowanie chirurgiczne u nosicieli mutacji proto-onkogenu RET].
Czarniecka A, Oczko-Wojciechowska M, Hajduk A, et al.
Endokrynologia Polska 2019; (70(4)):367-379 doi:10.5603/EP.a2019.0021.
PMID: 31489961 - 4
[Thyroid C cells and their pathology: Part 1: normal C cells, - C cell hyperplasia, - precursor of familial medullary thyroid carcinoma].
Ting S, Synoracki S, Schmid KW
Der Pathologe 2015; (36(3)):246-53 doi:10.1007/s00292-015-0019-x.
PMID: 25898937 - 5
Incidental thyroid C cell hyperplasia: clinical significance and implications in practice.
Sakorafas GH, Nasikas D, Thanos D, Gantzoulas S
Oncology research and treatment 2015; (38(5)):249-52 doi:10.1159/000381605.
PMID: 25966772 - 6
[Hereditary medullary thyroid cancer].
Fendrich V, Zahn A
Chirurgie (Heidelberg, Germany) 2023; (94(5)):393-399 doi:10.1007/s00104-023-01824-x.
PMID: 36799965 - 7
Thyroid C-Cell Biology and Oncogenic Transformation.
Cote GJ, Grubbs EG, Hofmann MC
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2015; (204()):1-39 doi:10.1007/978-3-319-22542-5_1.
PMID: 26494382 - 8
Prophylactic thyroidectomies in MEN2 syndrome: Management and outcomes.
Bussières V, Roy S, Deladoey J, et al.
Journal of pediatric surgery 2018; (53(2)):283-285 doi:10.1016/j.jpedsurg.2017.11.015.
PMID: 29336779 - 9
Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases.
Eckelt F, Vogel M, Geserick M, et al.
Clinical chemistry and laboratory medicine 2019; (57(8)):1242-1250.
PMID: 30794525 - 10
Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K, Raue F
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2015; (204()):139-56 doi:10.1007/978-3-319-22542-5_6.
PMID: 26494387 - 11
Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.
Frank-Raue K, Raue F
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2025; (223()):183-209 doi:10.1007/978-3-031-80396-3_7.
PMID: 40102258 - 12
Bilateral Medullary Thyroid Carcinoma in a 3-Year-Old Female Patient with Multiple Endocrine Neoplasia 2A Syndrome Undergoing Prophylactic Thyroidectomy: Should Current Guidelines Be Revised?
Al-Kurd A, Gross DJ, Zangen D, et al.
European thyroid journal 2018; (7(5)):267-271 doi:10.1159/000489170.
PMID: 30374431 - 13
Multiple endocrine neoplasia type 2 kindred with novel tandem RET mutations: Case report with an applied in silico mutational tolerance analysis.
Joshi RR, Heineman TE, Kutler DI, et al.
Head & neck 2016; (38 Suppl 1()):E1881-5 doi:10.1002/hed.24340.
PMID: 26876062 - 14
[Medullary thyroid carcinoma].
Tiedje V, Ting S, Dralle H, et al.
Der Internist 2015; (56(9)):1019-31 doi:10.1007/s00108-014-3638-z.
PMID: 26338063 - 15
Thresholds of Basal- and Calcium-Stimulated Calcitonin for Diagnosis of Thyroid Malignancy.
Băetu M, Olariu CA, Stancu C, et al.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2021; (53(12)):779-786 doi:10.1055/a-1661-4420.
PMID: 34687025 - 16
Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.
Raue F, Frank-Raue K
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2025; (223()):93-127 doi:10.1007/978-3-031-80396-3_4.
PMID: 40102255 - 17
Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F, Frank-Raue K
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2015; (204()):61-90 doi:10.1007/978-3-319-22542-5_3.
PMID: 26494384 - 18
Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A in children: a single centre experience.
Garcés Visier C, Espinoza Vega M, Guillén Redondo P, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(8)):889-893.
PMID: 31343983 - 19
Outcomes in Pediatric Thyroid Surgery Across Multiple Institutions.
Roy R, Babu A, Song Z, et al.
The Journal of surgical research 2025; (312()):55-67 doi:10.1016/j.jss.2025.05.008.
PMID: 40516151 - 20
Factors associated with postoperative hypocalcemia following thyroidectomy in childhood.
Spinelli C, Ghionzoli M, Bertocchini A, et al.
Pediatric blood & cancer 2022; (69(8)):e29576 doi:10.1002/pbc.29576.
PMID: 35129296 - 21
[Prophylactic thyroidectomy in RET proto-oncogen mutation].
Rodríguez Caraballo L, Gómez-Chacón Villalba J, Rodríguez Iglesias P, et al.
Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica 2017; (30(2)):100-104.
PMID: 28857533 - 22
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer.
Machens A, Dralle H
Best practice & research. Clinical endocrinology & metabolism 2019; (33(4)):101274 doi:10.1016/j.beem.2019.04.008.
PMID: 31043326
This page is for informational purposes only and does not replace professional medical advice. Treatment timelines for MEN2 and RET mutations are highly individualized, so always consult your child's pediatric endocrinologist and surgeon.
Get notified when new evidence is published on Tumor of endocrine glands.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.